Burden of disease, research funding and innovation in the UK: Do new health technologies reflect research inputs and need?
- 1 April 2013
- journal article
- research article
- Published by SAGE Publications in Journal of Health Services Research & Policy
- Vol. 18 (1_suppl) , 7-13
Abstract
Objectives: New and emerging health technologies (innovation outputs) do not always reflect conditions representing the greatest disease burden. We examine the role of research and development (R&D) funding in this relationship, considering whether areas with fewer innovative outputs receive an appropriate share of funding relative to their disease burden. Methods: We report a retrospective observational study, comparing burden of disease with R&D funding and innovation output. UK disability-adjusted life years (DALYs) and deaths came from the World Health Organization (WHO) 2004 Global Burden of Disease estimates; funding estimates from the UK Clinical Research Collaboration’s 2006 Health Research Analysis; and innovation output was estimated by the number of new and emerging technologies reported by the National Institute for Health Research (NIHR) Horizon Scanning Centre between 2000 and 2009. Results: Disease areas representing the biggest burden were generally associated with the most funding and innovation output; cancer, neuropsychiatric conditions and cardiovascular disease together comprised approximately two-thirds of DALYs, funding and reported technologies. Compared with DALYs, funding and technologies were disproportionately high for cancer, and technologies alone were disproportionately high for musculoskeletal conditions and endocrine/metabolic diseases. Neuropsychiatric conditions had comparatively few technologies compared to both DALYs and funding. The relationship between DALYs and innovation output appeared to be mediated by R&D funding. Conclusions: The relationship between burden of disease and new and emerging health technologies for different disease areas is partly dependent on the associated level of R&D funding (input). Discrepancies among key groups may reflect differential focus of research funding across disease areas.Keywords
This publication has 12 references indexed in Scilit:
- ANALYZING 10 YEARS OF EARLY AWARENESS AND ALERT ACTIVITY IN THE UNITED KINGDOMInternational Journal of Technology Assessment in Health Care, 2012
- Innovation and the Burden of Disease: Retrospective Observational Study of New and Emerging Health Technologies Reported by the EuroScan Network from 2000 to 2009Value in Health, 2012
- The answer is 17 years, what is the question: understanding time lags in translational researchJournal of the Royal Society of Medicine, 2011
- UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden?European Journal of Neurology, 2011
- NIH Disease Funding Levels and Burden of DiseasePLOS ONE, 2011
- Does the development of new medicinal products in the European Union address global and regional health concerns?Population Health Metrics, 2010
- Health research fundingBMJ, 2006
- Global Monitoring Report 20042004
- Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research fundingInternational Journal of Geriatric Psychiatry, 2001
- The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.Journal of Personality and Social Psychology, 1986